I. Amendments to the Claims:

This Listing of Claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A pharmaceutical composition comprising hydrocodone or a pharmaceutically acceptable salt thereof and naltrexone hydrochloride dihydrate ~~or a pharmaceutically acceptable salt thereof~~, wherein

said naltrexone ~~or pharmaceutically acceptable salt thereof~~ and said hydrocodone or the pharmaceutically acceptable salt thereof are in a ratio of from 0.011:1 to 0.0125:1, and the pharmaceutical composition comprises from 0.055 to 0.28 mg of said naltrexone ~~or pharmaceutically acceptable salt thereof~~.

Claim 2 (currently amended): The pharmaceutical composition of claim 1 comprising about 5 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.055 mg of said naltrexone ~~or pharmaceutically acceptable salt thereof~~.

Claim 3 (currently amended): The pharmaceutical composition of claim 1 comprising about 7.5 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.0825 mg of said naltrexone ~~or pharmaceutically acceptable salt thereof~~.

Claim 4 (currently amended): The pharmaceutical composition of claim 1 comprising about 10 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.11 mg of said naltrexone ~~or pharmaceutically acceptable salt thereof~~.

Claim 5 (currently amended): The pharmaceutical composition of claim 1 comprising about 15 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.165 mg of said naltrexone ~~or pharmaceutically acceptable salt thereof~~.

Claim 6 (previously presented): The pharmaceutical composition of claim 1 comprising about 20 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.22 mg of said naltrexone ~~or pharmaceutically acceptable salt thereof~~.

Claim 7 (currently amended): The pharmaceutical composition of claim 1 comprising about 5 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.0625 mg of said naltrexone ~~or pharmaceutically acceptable salt thereof~~.

Claim 8 (currently amended): The pharmaceutical composition of claim 1 comprising about 7.5 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.09375 mg of said naltrexone ~~or pharmaceutically acceptable salt thereof~~.

Claim 9 (currently amended): The pharmaceutical composition of claim 1 comprising about 10 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.125 mg of said naltrexone ~~or pharmaceutically acceptable salt thereof~~.

Claim 10 (currently amended): The pharmaceutical composition of claim comprising about 15 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.1875 mg of said naltrexone ~~or pharmaceutically acceptable salt thereof~~.

Claim 11 (currently amended): The pharmaceutical composition of claim 1 comprising about 20 mg of said hydrocodone or pharmaceutically acceptable salt thereof and 0.25 mg of said naltrexone ~~or pharmaceutically acceptable salt thereof~~.

Claim 12 (previously presented): The pharmaceutical composition of claim 1 further comprising a sustained release excipient which provides a sustained release of said hydrocodone or pharmaceutically acceptable salt thereof.

Claim 13 (previously presented): The pharmaceutical composition of claim 1 further comprising a sustained release excipient which provides a sustained release of said naltrexone or pharmaceutically acceptable salt thereof.

Claim 14 (currently amended): The pharmaceutical composition of claim 1 further comprising a sustained release excipient which provides a sustained release of said hydrocodone or pharmaceutically acceptable salt thereof and said naltrexone ~~or pharmaceutically acceptable salt thereof~~.

Claim 15 (previously presented): The pharmaceutical composition of claim 12, wherein the composition provides effective pain relief for at least 12 hours after steady state oral administration to human patients.

Claim 16 (previously presented): The pharmaceutical composition of claim 12, wherein the composition provides effective pain relief for at least 24 hours after steady state oral administration to human patients.

Claim 17 (currently amended): The pharmaceutical composition of claim 14, wherein said hydrocodone or pharmaceutically acceptable salt thereof and said naltrexone ~~or pharmaceutically acceptable salt thereof~~ are substantially interdispersed in said sustained release excipient.

Claim 18 (previously presented): The pharmaceutical composition of claim 1, wherein said hydrocodone is in the form of the bitartrate salt.

Claims 19-38 (cancelled).